IMGN901 is an investigational agent designed to kill cancer cells that express CD56, a protein. It consists of a CD56-binding antibody with a potent cancer cell killing agent, attached thereto using an engineered linker. IMGN901 is in Phase I trials for the treatment of CD56-expressing solid tumors and multiple myeloma. It is a wholly owned subsidiary of ImmunoGen.
About the presentationthe poster, ‘phase I trial IMGN901, used as monotherapy, in patients with heavily pre – CD56 – Positive Multiple Myeloma – A Preliminary safety and effectiveness Analysis is ‘presented at ASH from 6: 00 – 20.00 clock . Chanan-Khan is the lead investigator of the study.See stories such as this daily through Election Day at:.
The CPC resulted in significantly higher rates of the participation in 4 – year colleges and employment in click skilled jobs and significantly lower rates felony arrest and symptoms of depression during early adulthood. It is the first cost benefit analysis sustainable and large financed by public funds engaging to adulthood. From by the Eunice Kennedy Shriver nation Institute of Child Health and Human Development.